Table 1.
Nerve-sparing technique
|
P-value* | |||
---|---|---|---|---|
BNS | UNS | NNS | ||
Number of patients | 579 | 136 | 303 | |
Age at surgery, mean (years) | 59.977a | 63.62 | <0.001† | |
Body mass index (kg m−2) | 27.92 | 28.99 | 28.04 | <0.001† |
Race (%) | <0.001 | |||
White | 290 (50) | 88 (65) | 186 (62) | |
Black | 243 (42) | 43 (32) | 87 (29) | |
Other | 42 (7) | 5 (4) | 27 (9) | |
Biopsy Gleason score (%) | <0.001 | |||
<7 | 404 (70) | 84 (62) | 165 (52) | |
7 | 145 (25) | 35 (26) | 92 (31) | |
>7 | 27 (5) | 16 (12) | 43 (14) | |
Clinical stage (%) | <0.001 | |||
<T2b | 492 (87) | 112 (82) | 222 (74) | |
T2b | 37 (7) | 17 (13) | 50 (17) | |
>T2b | 39 (7) | 7 (5) | 27 (9) | |
Positive biopsy cores (%) | 0.33 | 0.36 | 0.44 | 0.037† |
PSA | 8.28 | 10.51 | 11.74 | 0.001† |
Pathological Gleason score (%) | <0.001 | |||
<7 | 309 (54) | 56 (42) | 108 (37) | |
7 | 231 (40) | 66 (49) | 133 (45) | |
>7 | 36 (6) | 12 (9) | 54 (18) | |
PSM | 217 (38) | 53 (40) | 124 (43) | 0.40 |
Capsular penetration (%) | 135 (20) | 67 (39) | 28 (61) | <0.001 |
Seminal vesicle involvement (%) | 38 (7) | 10 (8) | 43 (15) | <0.001 |
Positive lymph nodes (%) | 6 (1) | 3 (3) | 8 (3) | 0.25 |
Apical PSM | 77 (19) | 12 (18) | 27 (10) | 0.40 |
Bladder neck PSM | 17 (3) | 3 (2) | 20 (7) | 0.007 |
Recurrence | 128 (22) | 33 (25) | 119 (40) | <0.001 |
Abbreviations: BNS, bilateral nerve sparing; NNS, non-NS; PSA, prostate-specific antigen; PSM, positive surgical margin; UNS, unilateral nerve sparing.
P-value by chi-square test except where noted.
P-value by analysis of variance.
BNS and UNS groups combined to compare age to NNS groups.